Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E₂ Receptor EP4 Pathway

Figure 2

Paricalcitol increased EP4 expression in HK-2 cells. (a) Paricalcitol increased the mRNA level of EP4 but did not affect mRNA expression of EP1–EP3. (b) The cellular membrane fraction of EP4 protein expression was significantly elevated in a dose-dependent manner in response to paricalcitol treatment. (c) The cellular membrane fraction of EP4 protein expression was significantly increased in ischemia-exposed cells and was further increased by treatment with paricalcitol (2 ng/ml). Each column represents the mean ± SEM of three independent experiments. versus control.

(a)

(b)

(c)